PE20131085A1 - A NEW CONJUGATE OF COLOGNE GRANULOCYTE-STIMULATING FACTOR (G-CSF) WITH POLYETHYLENE GLYCOL - Google Patents

A NEW CONJUGATE OF COLOGNE GRANULOCYTE-STIMULATING FACTOR (G-CSF) WITH POLYETHYLENE GLYCOL

Info

Publication number
PE20131085A1
PE20131085A1 PE2013000083A PE2013000083A PE20131085A1 PE 20131085 A1 PE20131085 A1 PE 20131085A1 PE 2013000083 A PE2013000083 A PE 2013000083A PE 2013000083 A PE2013000083 A PE 2013000083A PE 20131085 A1 PE20131085 A1 PE 20131085A1
Authority
PE
Peru
Prior art keywords
csf
stimulating factor
cologne
granulocyte
polyethylene glycol
Prior art date
Application number
PE2013000083A
Other languages
Spanish (es)
Inventor
Tatyana Veniaminovna Chernovskaya
Lev Alexandrovich Denisov
Elena Georgievna Rudenko
Dmitriy Valentinovich Morozov
Original Assignee
Biocad Cjsc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45567857&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20131085(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biocad Cjsc filed Critical Biocad Cjsc
Publication of PE20131085A1 publication Critical patent/PE20131085A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)

Abstract

REFERIDA A UN FACTOR ESTIMULANTE DE COLONIA DE GRANULOCITOS (G-CSF) CONJUGADO CON UN MONOMETOXIPOLIETILENGLICOL DE FORMULA (I), DONDE n ES UN ENTERO DE 681 A 1000; m ES UN ENTERO MAYOR O IGUAL A 4; N(ALFA)H-G-CSF ES UN POLIPEPTIDO NATURAL O RECOMBINANTE. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHO CONJUGADO ES UTIL EN EL TRATAMIENTO DE LEUCOPENIA, NEUTROPENIA EN PACIENTES CON QUIMIOTERAPIA MIELOSUPRESIVA, PACIENTES CON NEUTROPENIA CRONICA, ENTRE OTROSREFERRING TO A COLONY STIMULATING FACTOR OF GRANULOCYTES (G-CSF) CONJUGATED WITH A MONOMETOXIPOLYETHYLENE GLYCOL OF FORMULA (I), WHERE n IS AN INTEGER FROM 681 TO 1000; m IS AN INTEGER GREATER THAN OR EQUAL TO 4; N (ALPHA) H-G-CSF IS A NATURAL OR RECOMBINANT POLYPEPTIDE. IT ALSO REFERS TO A PHARMACEUTICAL COMPOSITION. SAID CONJUGATE IS USEFUL IN THE TREATMENT OF LEUCOPENIA, NEUTROPENIA IN PATIENTS WITH MYELOSUPPRESSIVE CHEMOTHERAPY, PATIENTS WITH CHRONIC NEUTROPENIA, AMONG OTHERS

PE2013000083A 2010-08-13 2011-07-19 A NEW CONJUGATE OF COLOGNE GRANULOCYTE-STIMULATING FACTOR (G-CSF) WITH POLYETHYLENE GLYCOL PE20131085A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010133875/10A RU2446173C1 (en) 2010-08-13 2010-08-13 New functional, high-purity stable conjugate of granulocyte colony-stimulating factor (g-csf) and polyethylene glycol with prolonged biological action, applicable for medical purposes, and based immunobiological agent

Publications (1)

Publication Number Publication Date
PE20131085A1 true PE20131085A1 (en) 2013-10-10

Family

ID=45567857

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013000083A PE20131085A1 (en) 2010-08-13 2011-07-19 A NEW CONJUGATE OF COLOGNE GRANULOCYTE-STIMULATING FACTOR (G-CSF) WITH POLYETHYLENE GLYCOL

Country Status (17)

Country Link
KR (1) KR101549457B1 (en)
CN (1) CN103140499B (en)
CL (1) CL2013000400A1 (en)
CO (1) CO6670557A2 (en)
CR (1) CR20130020A (en)
CU (1) CU24139B1 (en)
DO (1) DOP2013000003A (en)
EA (1) EA019043B1 (en)
EC (1) ECSP13012399A (en)
MA (1) MA34525B1 (en)
MY (1) MY160732A (en)
NI (1) NI201300007A (en)
PE (1) PE20131085A1 (en)
RS (1) RS20130094A1 (en)
RU (1) RU2446173C1 (en)
SG (1) SG187572A1 (en)
WO (1) WO2012021088A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012110057A1 (en) 2011-02-15 2012-08-23 Chemisches Institut Schaefer Ag Cefuroxime safety kit
ES2691493T3 (en) 2012-06-07 2018-11-27 Childrens Hospital Los Angeles Methods to treat neutropenia using retinoid agonists
CN103908427B (en) * 2013-01-05 2014-12-17 石药集团百克(山东)生物制药有限公司 Polyethylene glycol modified rhG-CSF injection and preparation method thereof
RU2535002C2 (en) * 2013-04-04 2014-12-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии" Сибирского отделения Российской академии медицинских наук Method for correction of remote consequences of spermatogenesis caused by cytostatic exposure
AU2015219038B2 (en) 2014-02-18 2018-10-18 Children's Hospital Los Angeles Compositions and methods for treating neutropenia
JP6742300B2 (en) * 2014-07-14 2020-08-19 ジェンノヴァ バイオファーマシューティカルズ リミテッド Novel process for purification of rHu-GCSF
IL247369B (en) * 2016-08-18 2018-08-30 B G Negev Tech And Applications Ltd Modified m-csf polypeptides and use thereof
KR102020995B1 (en) * 2017-10-30 2019-09-16 한국코러스 주식회사 A method of preparing gcsf and polyol_conjugated conjugates with high yield
BR112022018501A2 (en) * 2020-03-17 2022-10-25 Drugrecure Aps LIQUID FORMULATION OF GM-CSF FOR INHALATION

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE135370T1 (en) * 1988-12-22 1996-03-15 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
US5252714A (en) * 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
KR20040083268A (en) * 2003-03-21 2004-10-01 한미약품 주식회사 Human granulocyte-colony stimulating factor conjugate having enhanced stability in blood and process for the preparation thereof
RU2278870C2 (en) * 2004-08-30 2006-06-27 Закрытое Акционерное Общество "Биокад" Method for preparing, isolating, purifying and stabilizing human recombinant granulocytic colony-stimulating factor useful for medicinal using and immunobiological agent based on thereof
WO2007084460A2 (en) * 2006-01-18 2007-07-26 Qps, Llc Pharmaceutical compositions with enhanced stability
JP2009541333A (en) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド Modified ribonuclease

Also Published As

Publication number Publication date
CU24139B1 (en) 2015-12-23
EA201101035A1 (en) 2012-02-28
RU2446173C1 (en) 2012-03-27
CO6670557A2 (en) 2013-05-15
DOP2013000003A (en) 2013-07-31
CN103140499A (en) 2013-06-05
MA34525B1 (en) 2013-09-02
KR101549457B1 (en) 2015-09-02
SG187572A1 (en) 2013-03-28
MY160732A (en) 2017-03-15
WO2012021088A1 (en) 2012-02-16
ECSP13012399A (en) 2013-05-31
NI201300007A (en) 2014-05-26
KR20130043167A (en) 2013-04-29
EA019043B1 (en) 2013-12-30
CN103140499B (en) 2014-12-17
CL2013000400A1 (en) 2013-07-26
RS20130094A1 (en) 2013-08-30
CR20130020A (en) 2013-02-20
CU20130012A7 (en) 2013-04-19

Similar Documents

Publication Publication Date Title
PE20131085A1 (en) A NEW CONJUGATE OF COLOGNE GRANULOCYTE-STIMULATING FACTOR (G-CSF) WITH POLYETHYLENE GLYCOL
ES2619309T3 (en) Sulfated hyaluronic acid for the treatment of degenerative osteoarthritis
PE20140382A1 (en) IL-2 DERIVED POLYPEPTIDES WITH AGONIST ACTIVITY FOR CANCER THERAPY AND CHRONIC INFECTIONS
MY188960A (en) Cyclic boronic acid ester derivatives and therapeutic uses thereof
CL2013000018A1 (en) Compounds derived from indolizine, their preparation procedure; pharmaceutical composition; and use in the treatment of cancer, among others.
BR112012016853A2 (en) "pharmaceutical compositions for oral administration of insulin peptides".
NZ594056A (en) New stable formulations of recombinant human albumin-human granulocyte colony stimulating factor fusion protein
CO6501124A2 (en) IMMUNOMODULATING POLYPEPTIDES DERIVED IS THE IL 2 AND ITS THERAPEUTIC USE IN CANCER AND IN CHRONIC INFECTIONS
BR112013026363A2 (en) nanosuspensions of freeze-dried drug
MY163215A (en) Thermogelling anaesthetic compositions
MY160922A (en) Polyethylene glycol conjugated blood coagulation factor vii
EA201370006A1 (en) LOCAL PHARMACEUTICAL COMPOSITION CONTAINING FLURBIPROPHEN
IN2014DN00277A (en)
PE20150288A1 (en) POLYMER BASED DIALYSATE
EA201290941A1 (en) CONJUGATED BLOOD COAGULATION FACTOR VIIa
CL2011001427A1 (en) Compounds derived from 4-azetidinyl-1-heteroaryl-cyclohexanol; pharmaceutical composition; and use in the treatment of diseases such as epoc, atherosclerosis, rheumatoid arthritis, among others.
IN2014DN08598A (en)
PE20142325A1 (en) COMPOSITIONS DERIVED FROM CHITOSANE
EA201390090A1 (en) DISINFECTANT AND ANTI-SECONDARY DRUG WITH A REDUCED CONTENT OF IODINE
MX2015013263A (en) Polyalkylene oxide valerate hemoglobin conjugates.
AR083770A1 (en) METHODS AND COMPOSITIONS, KIT
MX343589B (en) Leukotoxin e/d as a new anti-inflammatory agent and microbicide.
BR112015022730A2 (en) rfviii formulations, method for covalent conjugation of rfviii to a biocompatible polymer and use of rfviii in the preparation of rfviii formulation for treating hemophilia a
BR112013006651A2 (en) composition and cocrystal of l-proline aprepitant
PH12015500807A1 (en) Tgf�-derived polypeptides and uses thereof

Legal Events

Date Code Title Description
FC Refusal